Connection

Jean-Charles Soria to Carcinoma, Squamous Cell

Back to Details
This is a "connection" page, showing publications Jean-Charles Soria has written about Carcinoma, Squamous Cell.
Jean-Charles Soria
Connection Strength
0.935
Carcinoma, Squamous Cell
  1. Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. JAMA Oncol. 2018 09 01; 4(9):1189-1197.
    View in: PubMed
    Score: 0.391
  2. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res. 2012 May 01; 18(9):2443-51.
    View in: PubMed
    Score: 0.250
  3. Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. Clin Lung Cancer. 2018 01; 19(1):74-83.e11.
    View in: PubMed
    Score: 0.090
  4. A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers. Clin Cancer Res. 2017 Sep 15; 23(18):5366-5373.
    View in: PubMed
    Score: 0.090
  5. Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. Lung Cancer. 2017 07; 109:101-108.
    View in: PubMed
    Score: 0.089
  6. A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours. Eur J Cancer. 2018 11; 104:1-8.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.